A Critical Appraisal of Withania somnifera and Curcuma amada Transdermal Patches for Inflammation and Pain
Transdermal patches carrying extracts of Withania somnifera have been proposed as a safer alternative to oral non-steroidal anti-inflammatory drugs for localised inflammation and musculoskeletal pain. The pharmacological case is good and, unusually for a botanical, it includes direct evidence in skin: a root extract has been shown to suppress mitogen-activated protein kinase and nuclear factor kappa B signalling in human keratinocytes and to lower tumour necrosis factor alpha in a murine skin wound model. The formulation literature has not kept pace with that pharmacology. This review sets out the phytochemistry, the mechanistic evidence, the physicochemical constraints on percutaneous delivery of withanolides, the patch architecture conventionally used, and the evaluation battery conventionally applied. It then examines four problems that recur across published studies: an analytical method without specificity, a release test reported as a permeation test, a payload arithmetic that is almost never shown, and a marker assumption that the one study to look directly at skin does not support. Each is remediable, and the final sections propose what a defensible study would require.
Authors
- Anjali Patil
- Mohd Saleemuddin Farooqui
- Sandip Fulzele
- Nisha Purke
- Sayyad Sajauddin Gulab
Institutions
- Hindu College of Pharmacy (IN)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24414922
- Primary Topic
- Advancements in Transdermal Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00